Greenwald Mark K
Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 48201, USA.
Neurobiol Stress. 2018 Aug 11;9:84-104. doi: 10.1016/j.ynstr.2018.08.003. eCollection 2018 Nov.
Stress-related substance use is a major challenge for treating substance use disorders. This selective review focuses on emerging pharmacotherapies with potential for reducing stress-potentiated seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids (i.e., key phenotypes for the most commonly abused substances). I evaluate neuropharmacological mechanisms in experimental models of drug-maintenance and relapse, which translate more readily to individuals presenting for treatment (who have initiated and progressed). An affective/motivational systems model (three dimensions: valence, arousal, control) is mapped onto a systems biology of addiction approach for addressing this problem. Based on quality of evidence to date, promising first-tier neurochemical receptor targets include: noradrenergic (α1 and β antagonist, α2 agonist), -opioid antagonist, nociceptin antagonist, orexin-1 antagonist, and endocannabinoid modulation (e.g., cannabidiol, FAAH inhibition); second-tier candidates may include corticotropin releasing factor-1 antagonists, serotonergic agents (e.g., 5-HT reuptake inhibitors, 5-HT3 antagonists), glutamatergic agents (e.g., mGluR2/3 agonist/positive allosteric modulator, mGluR5 antagonist/negative allosteric modulator), GABA-promoters (e.g., pregabalin, tiagabine), vasopressin 1b antagonist, NK-1 antagonist, and PPAR-γ agonist (e.g., pioglitazone). To address affective/motivational mechanisms of stress-related substance use, it may be advisable to combine agents with actions at complementary targets for greater efficacy but systematic studies are lacking except for interactions with the noradrenergic system. I note clinically-relevant factors that could mediate/moderate the efficacy of anti-stress therapeutics and identify research gaps that should be pursued. Finally, progress in developing anti-stress medications will depend on use of reliable CNS biomarkers to validate exposure-response relationships.
与压力相关的物质使用是治疗物质使用障碍的一项重大挑战。本选择性综述聚焦于具有减少压力增强的尼古丁、酒精、大麻、可卡因和阿片类药物(即最常滥用物质的关键表型)寻求和消费潜力的新兴药物疗法。我评估了药物维持和复发实验模型中的神经药理学机制,这些机制更容易转化到前来接受治疗(已经开始并发展到一定阶段)的个体身上。一种情感/动机系统模型(三个维度:效价、唤醒、控制)被映射到一种成瘾的系统生物学方法上来解决这个问题。基于目前的证据质量,有前景的一线神经化学受体靶点包括:去甲肾上腺素能(α1和β拮抗剂、α2激动剂)、μ-阿片拮抗剂、孤啡肽拮抗剂、食欲素-1拮抗剂和内源性大麻素调节(如大麻二酚、脂肪酸酰胺水解酶抑制);二线候选药物可能包括促肾上腺皮质激素释放因子-1拮抗剂、血清素能药物(如5-羟色胺再摄取抑制剂、5-羟色胺3拮抗剂)、谷氨酸能药物(如代谢型谷氨酸受体2/3激动剂/正变构调节剂、代谢型谷氨酸受体5拮抗剂/负变构调节剂)、γ-氨基丁酸促进剂(如普瑞巴林、噻加宾)、血管加压素1b拮抗剂、神经激肽-1拮抗剂和过氧化物酶体增殖物激活受体-γ激动剂(如吡格列酮)。为了解决与压力相关的物质使用的情感/动机机制,将作用于互补靶点的药物联合使用可能会提高疗效,但除了与去甲肾上腺素能系统的相互作用外,缺乏系统性研究。我指出了可能介导/调节抗应激治疗疗效的临床相关因素,并确定了应加以研究的差距。最后,抗应激药物开发的进展将取决于使用可靠的中枢神经系统生物标志物来验证暴露-反应关系。